Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.485 AUD | +1.04% | +8.99% | -14.91% |
May. 15 | Imricor Medical Systems, Inc. to Commence 2 Clinical Trials, VISABL-AFL and VISABL-VT | CI |
May. 15 | Transcript : Imricor Medical Systems, Inc. - Shareholder/Analyst Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.91% | 65.33M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.61B |
- Stock Market
- Equities
- IMR Stock
- News Imricor Medical Systems, Inc.
- Imricor's Diagnostic Catheter Granted CE Mark Approval for European Market Sales; Shares Decline 4%